The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
复制标题
DOI:
10.1016/j.ccell.2020.10.001
复制
发表时间:
2021-02-08
期刊:
影响因子:
50.3
通讯作者:
Kurzrock R
中科院分区:
文献类型:
--
作者:
Jardim DL;Goodman A;de Melo Gagliato D;Kurzrock R
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T-cells. To evade immune eradication, cancers exploit checkpoints that dampen T-cell reactivity. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enabling T-cell reactivation; however, response biomarkers are required, as most patients do not benefit. Higher TMB results in more neo-antigens, increasing chances for T-cell recognition, and clinically correlates with better ICI outcomes. Nevertheless, TMB is an imperfect response biomarker. A composite predictor that also includes critical variables, such as MHC and T-cell receptor repertoire, is needed.
登录
查看更多内容
影响因子:
30.8
作者:
Burns, Michael B.;Temiz, Nuri A.;Harris, Reuben S.
通讯作者:
Harris, Reuben S.
影响因子:
4.6
作者:
Bonneville R;Krook MA;Kautto EA;Miya J;Wing MR;Chen HZ;Reeser JW;Yu L;Roychowdhury S
通讯作者:
Roychowdhury S
影响因子:
45.3
作者:
Ballman, Karla V.
通讯作者:
Ballman, Karla V.
DOI:
10.1056/nejmoa1613493
发表时间:
2017-06-22
期刊:
The New England journal of medicine
影响因子:
--
作者:
Carbone DP;Reck M;Paz-Ares L;Creelan B;Horn L;Steins M;Felip E;van den Heuvel MM;Ciuleanu TE;Badin F;Ready N;Hiltermann TJN;Nair S;Juergens R;Peters S;Minenza E;Wrangle JM;Rodriguez-Abreu D;Borghaei H;Blumenschein GR Jr;Villaruz LC;Havel L;Krejci J;Corral Jaime J;Chang H;Geese WJ;Bhagavatheeswaran P;Chen AC;Socinski MA;CheckMate 026 Investigators
通讯作者:
CheckMate 026 Investigators
影响因子:
7.2
作者:
Budczies, Jan;Seidel, Anja;Denkert, Carsten
通讯作者:
Denkert, Carsten